Renal Solutions' Allient haemodialysis:
This article was originally published in Clinica
Executive Summary
Renal Solutions has received US FDA 510(k) clearance to sell an improved version of its Allient sorbent haemodialysis system for chronic and acute haemodialysis applications. The product, which includes the firm's Sorb and Hisorb series of cartridges, incorporates advanced haemocompatible materials in its Pulsar blood pump component, said the Warrendale, Pennsylvania company. Comprising what the firm describes as a unique, pressure-limited, two-chamber design, the Pulsar pump represents "the first significant step forward in dialysis blood pump design in several decades", Renal Solutions claimed. The firm added that its Allient product opened new treatment options, by virtue of its ability to provide short, standard or extended duration haemodialysis therapy using just 1 and 0.5 gallons of ordinary drinking water.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.